Quick Answer
Adaptive Biotechnologies Corp reported Total Revenue of $276.98 million for the year ending 2025.
- Adaptive Biotechnologies Corp showed an increase of +54.8% in Total Revenue from 2024 to 2025.
- This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $11.57 million | Q3 2018: $17.19 million | Q1 2019: $12.67 million | Q2 2019: $22.14 million | Q3 2019: $26.06 million | Q1 2020: $20.91 million | Q2 2020: $20.99 million | Q3 2020: $26.30 million | Q1 2021: $38.44 million | Q2 2021: $38.51 million | Q3 2021: $39.47 million | Q1 2022: $38.62 million | Q2 2022: $43.66 million | Q3 2022: $47.83 million | Q1 2023: $37.65 million | Q2 2023: $48.93 million | Q3 2023: $37.92 million | Q1 2024: $41.87 million | Q2 2024: $43.19 million | Q3 2024: $46.44 million | Q1 2025: $52.44 million | Q2 2025: $58.88 million | Q3 2025: $93.97 million.
- Over the full 9 years of available data (2017 to 2025), Adaptive Biotechnologies Corp's Total Revenue has grown by 620.4%.
- Historical annual values: Fiscal year 2025: $276.98 million | Fiscal year 2024: $178.96 million | Fiscal year 2023: $170.28 million | Fiscal year 2022: $185.31 million | Fiscal year 2021: $154.34 million | Fiscal year 2020: $98.38 million | Fiscal year 2019: $85.07 million | Fiscal year 2018: $55.66 million | Fiscal year 2017: $38.45 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: